Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil in HFpEF with combined post- and pre-capillary pulmonary hypertension
2017-003688-37Phase 3Completed
- Sponsor
- Philipps-Universität Marburg
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of tadalafil in heart failure with preserved ejection fraction (HFpEF), combined post-capillary and pre-capillary pulmonary hypertension and pulmonary hypertension (PH), sponsored by Philipps-Universität Marburg. Primary endpoint: Event-free survival. Started May 2018; status: completed.
02
Drugs
tadalafil
03
Conditions
heart failure with preserved ejection fraction (HFpEF)combined post-capillary and pre-capillary pulmonary hypertensionpulmonary hypertension (PH)
Beyond the preview
Go deeper on 2017-003688-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003688-37.